TERAPIA CELULAR Y MEDICINA REGENERATIVA
Universidad de Navarra
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Universidad de Navarra (21)
2023
-
Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion
Cancer Medicine, Vol. 12, Núm. 16, pp. 16788-16792
-
Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)
Bone Marrow Transplantation
-
Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution
eLife, Vol. 12
2022
-
Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome
Frontiers in Immunology, Vol. 13
-
Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes
Leukemia and Lymphoma, Vol. 63, Núm. 5, pp. 1227-1235
-
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients
Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550
-
The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes
Nature Communications, Vol. 13, Núm. 1
2021
-
Long-term efficacy of autologous bone marrow mesenchymal stromal cells for treatment of knee osteoarthritis
Journal of Translational Medicine
-
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations
British Journal of Haematology, Vol. 194, Núm. 4, pp. 708-717
2020
-
Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study
EClinicalMedicine, Vol. 25
-
Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus (Frontiers in Immunology, (2019), 10, 10.3389/fimmu.2019.01151)
Frontiers in Immunology
-
Distinct mutational pattern of myelodysplastic syndromes with and without 5q– treated with lenalidomide
British Journal of Haematology
-
Phase II multicenter randomized controlled clinical trial on the efficacy of intra-articular injection of autologous bone marrow mesenchymal stem cells with platelet rich plasma for the treatment of knee osteoarthritis
Journal of Translational Medicine, Vol. 18, Núm. 1
-
Spanish Cell Therapy Network (TerCel): 15 years of successful collaborative translational research
Cytotherapy, Vol. 22, Núm. 1, pp. 1-5
2019
-
Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus
Frontiers in Immunology, Vol. 10, Núm. JUN
2018
2016
2014
-
Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease
Biology of Blood and Marrow Transplantation, Vol. 20, Núm. 10, pp. 1580-1585
2013
-
Response to lenalidomide in myelodysplastic syndromes with del(5q): Influence of cytogenetics and mutations
British Journal of Haematology, Vol. 162, Núm. 1, pp. 74-86
-
Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing
Genes Chromosomes and Cancer, Vol. 52, Núm. 12, pp. 1167-1177